Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alpha Tau Medical Ltd. is conducting a pivotal clinical study titled ‘A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma.’ The study aims to evaluate the efficacy and safety of Alpha DaRT224 in treating patients with recurrent cutaneous squamous cell carcinoma, focusing on objective response rate and duration of response.
The intervention being tested is the DaRT seeds, a type of device designed for intratumoral administration. This treatment involves inserting DaRT seeds into tumors, which are then reassessed and removed after a few weeks to measure the treatment’s effectiveness.
This interventional study follows a single-group model without masking, aimed at treatment. It is an open-label trial, meaning both researchers and participants know the treatment being administered.
The study began on April 1, 2022, and the latest update was submitted on September 3, 2025. These dates are crucial as they indicate the study’s progress and the timeline for obtaining results.
The update on this study could influence Alpha Tau Medical Ltd.’s stock performance by potentially boosting investor confidence if the results are positive. The study’s progress is also relevant in the context of the competitive landscape of cancer treatment technologies.
The study is ongoing, and further details are available on the ClinicalTrials portal.